From the Zeno's paradoxes to novel immunotherapeutic agents for kidney cancer: moving from an era of wrong premises and conclusions to a better comprehension of immunology

Bibliography

• Porta C, Paglino C, Imarisio I, Bonomi L. Cytokine-based immunotherapy for advanced kidney cancer: past results and future perspectives in the era of molecularly targeted agents. Sci World J 2007;7:837-49
   Web of Science ®Google Scholar
• Trulson A, Nilsson S, Venge P. The eosinophil granule proteins in serum, but not the oxidative metabolism of the blood eosinophils, are increased in cancer. Br J Haematol 1997;98:312-14
   PubMed Web of Science ®Google Scholar
• Moroni M, Porta C, Gritti D, et al. Cationic protein-rich supernatants of cultured eosinophils from IL-2-treated patients have no cytotoxic activity on human renal cell carcinoma and melanoma cells: a preliminary report. Ann NY Acad Sci 1997;832:295-303
   PubMed Web of Science ®Google Scholar
• Porta C, Moroni M, De Amici M. Eosinophils and serum eosinophilic cationic proteins in interleukin-2-based immunotherapy for cancer. Br J Haematol 1998;100:607-9
   PubMed Web of Science ®Google Scholar
• Moroni M, Porta C, De Amici M, et al. Eosinophils and C4 predict clinical failure of combination immunotherapy with very low dose subcutaneous interleukin-2 and interferon in renal cell carcinoma patients. Haematologica 2000;85:298-303
   PubMed Web of Science ®Google Scholar
• Porta C, Rizzo V, Zimatore M, et al. Intrapleural interleukin-2 induces nitric oxide production in pleural effusions from malignant mesothelioma: a possible mechanism of interleukin-2-mediated cytotoxicity? Lung Cancer 2002;38:159-62
   PubMed Web of Science ®Google Scholar
• Ochoa JB, Curti B, Peitzman AB, et al. Increased circulating nitrogen oxides after human tumor immunotherapy: correlation with toxic hemodynamic changes [published erratum appears in J Natl Cancer Inst 1992;84:1291]. J Natl Cancer Inst 1992;84:864-7
   PubMed Web of Science ®Google Scholar
• Porta C, Moroni M, Bobbio-Pallavicini E, et al. Nitrate plasma level as a marker of nitric oxide production after subcutaneous interleukin 2 immunotherapy. J Natl Cancer Inst 1997;89:1545
   PubMed Web of Science ®Google Scholar
• Porta C, Danova M, Orengo AM, et al. Interleukin-2 induces cell cycle perturbations leading to cell growth inhibition and death in malignant mesothelioma cells in vitro. J Cell Physiol 2000;185:126-34
   PubMed Web of Science ®Google Scholar
• Antony PA, Restifo NP. CD4+CD25+ T regulatory cells, immunotherapy of cancer, and Interleukin-2. J Immunother 2005;28:120-8
   PubMed Web of Science ®Google Scholar
• Bracarda S, Eggermont AM, Samuelsson J. Redefining the role of interferon in the treatment of malignant diseases. Eur J Cancer 2010;46:284-97
   PubMed Web of Science ®Google Scholar
• Bracarda S, Porta C, Boni C, et al. Could interferon still play a role in metastatic renal cell carcinoma? A randomized study of two schedules of sorafenib plus interferon-alpha 2a (RAPSODY). Eur Urol 2013;63:254-61
   PubMed Web of Science ®Google Scholar
• Negrier S, Perol D, Ravaud A, et al. Medroxyprogesterone, interferon alfa-2a, interleukin 2, or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis: results of a randomized controlled trial. Cancer 2007;110:2468-77
   PubMed Web of Science ®Google Scholar
• Negrier S, Gomez F, Douillard JY, et al. Prognostic factors of response or failure of treatment in patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Francais d'Immunotherapie. World J Urol 2005;23:161-5
   PubMed Web of Science ®Google Scholar
• Negrier S, Perol D, Ravaud A, et al. Randomized study of intravenous versus subcutaneous interleukin-2, and IFN alpha in patients with good prognosis metastatic renal cancer. Clin Cancer Res 2008;14:5907-12
   PubMed Web of Science ®Google Scholar
• Pavone L, Andrulli S, Santi R, et al. Long-term treatment with low doses of interleukin-2 and interferon-alpha: immunological effects in advanced renal cell cancer. Cancer Immunol Immunother 2001;50:82-6
   PubMed Web of Science ®Google Scholar
• Pavone L, Fanti G, Bongiovanni C, et al. Natural killer cell cytotoxicity is enhanced by very low doses of rIL-2 and rIFN-alpha in patients with renal cell carcinoma. Med Oncol 2009;26:38-44
   PubMed Web of Science ®Google Scholar
• Buti S, Rovere RK, Donini M, et al. Changes in lymphocyte count induced by repeated cycles with low-dose interleukin-2 and interferon-alpha in 146 patients with renal cell carcinoma. Tumori 2012;98:45-52
   PubMed Web of Science ®Google Scholar
• Clement JM, McDermott DF. The high-dose aldesleukin (IL-2) "SELECT" trial: a trial designed to prospectively validate predictive models of response to high-dose IL-2 treatment in patients with metastatic renal cell carcinoma. Clin Genitourin Cancer 2009;7:E7-9
   Web of Science ®Google Scholar
• Minasian LM, Motzer RJ, Gluck L, et al. Interferon alfa-2a in advanced renal cell carcinoma: treatment results and survival in 159 patients with long-term follow-up. J Clin Oncol 1993;11:1368-75
   PubMed Web of Science ®Google Scholar
• Klapper JA, Downey SG, Smith FO, et al. High-dose interleukin-2 for the treatment of metastatic renal cell carcinoma: a retrospective analysis of response and survival in patients treated in the surgery branch at the National Cancer Institute between 1986 and 2006. Cancer 2008;113:293-301
   PubMed Web of Science ®Google Scholar
• Bradley DA, Redman BG. The times they are a-changin' (Bob Dylan, 1964). Cancer 2007;110:2366-9
   PubMed Web of Science ®Google Scholar
• Postow MA, Harding J, Wolchok JD. Targeting immune checkpoints: releasing the restraints on anti-tumor immunity for patients with melanoma. Cancer J 2012;18:153-9
   PubMed Web of Science ®Google Scholar
• Zitvogel L, Kroemer G. Targeting PD-1/PD-L1 interactions for cancer immunotherapy. Oncoimmunology 2012;1:1223-5
   PubMed Web of Science ®Google Scholar
• Maio M, Di Giacomo AM, Robert C, Eggermont AM. Update on the role of ipilimumab in melanoma and first data on new combination therapies. Curr Opin Oncol 2013;25:166-72
   Google Scholar
• Bockorny B, Dasanu CA. Intrinsic immune alterations in renal cell carcinoma and emerging immunotherapeutic approaches. Expert Opin Biol Ther 2013;13(6):911-25
   PubMed Web of Science ®Google Scholar